Oral R115866 in the treatment of moderate to severe facial acne vulgaris: an exploratory study.

Autor: Verfaille CJ; Department of Dermatology, GROW, Maastricht University, Maastricht, The Netherlands. cverfaille@barriertherapeutics.be, Coel M, Boersma IH, Mertens J, Borgers M, Roseeuw D
Jazyk: angličtina
Zdroj: The British journal of dermatology [Br J Dermatol] 2007 Jul; Vol. 157 (1), pp. 122-6. Date of Electronic Publication: 2007 Apr 25.
DOI: 10.1111/j.1365-2133.2007.07896.x
Abstrakt: Background: R115866 (Rambazole; Barrier Therapeutics NV, Geel, Belgium), a new-generation retinoic acid metabolism-blocking agent, is a nonretinoid compound enhancing intracellularly the endogenous levels of all-trans-retinoic acid by blocking its catabolism. By virtue of this property, and the proven positive effects of retinoids in the treatment of acne, R115866 could potentially be a useful drug for acne.
Objectives: To explore the efficacy, safety and tolerability of systemic R115866 in male patients with moderate to severe facial acne vulgaris (at least 15 papules and/or pustules and at least two nodulocystic lesions).
Methods: In this exploratory trial, 17 patients were treated with oral R115866 1 mg once daily for 12 weeks, followed by a 4-week treatment-free period.
Results: At the end of treatment (week 12, n = 16) a mean reduction in inflammatory lesion count of 77.4% (P < 0.001), in noninflammatory lesion count of 58.3% (P < 0.001) and in total lesion count of 76.0% (P < 0.001) was observed as compared with baseline. All lesion counts were significantly reduced from week 4 onwards. Mild side-effects were reported occasionally.
Conclusions: The current data indicate that treatment with oral R115866 1 mg once daily for 12 weeks in patients with moderate to severe facial acne vulgaris is efficacious and well tolerated and merits further investigation.
Databáze: MEDLINE
Externí odkaz: